Turkey’s $2.6Bn Hospital Medtech Debts Create Problems On Top Of COVID-19
Turkey’s efforts to control rising rates of COVID-19 are compromising the ability of hospitals to pay their debts to medtech and pharmaceutical companies. The government has devised a payments plan, but there is catch.
You may also be interested in...
A plan to set up a Directorate of Health Industries within the Office of the Presidency has been welcomed by Turkish medtechs, who see it as opportunity to highlight to President Erdoğan ongoing industry problems such as late payments.
The devaluation of the Turkish Lira since May is making imports of medical devices more expensive and putting hospital procurement under renewed pressure. The local medtech industry associations TUMDEF and ARTED describe the problems ̶ and the solutions ̶ to Medtech Insight.
Turkish medtechs’ demands for payment of their outstanding hospital debts went unheeded in 2021, but the government has finally started a payment process. It is not evenly applied, and has started in a small way, but the industry feels encouraged on more than one count.